Tag:
Rib-X Pharmaceuticals
Latest Headlines
Latest Headlines
Cancer Genetics' IPO delayed amid Facebook frenzy
Seeking Alpha reasoned this week that Cancer Genetics' IPO might be small enough to slip through even though Wall Street has been bracing for the blockbuster maiden offering of Facebook. Guess not.
Rib-X Pharma delays IPO after price halved
Before postponing the IPO, Rib-X was aiming to raise $65 million in the offering.
RNAi developer Arrowhead snags startup Alvos in stock deal
Arrowhead Research has bought Alvos Therapeutics and the small company's peptides that home in on tumor targets.
Trius shares surge as antibiotic matches Zyvox in pivotal PhIII
Shares of Trius Therapeutics ( $TSRX ) surged on the news that its late-stage antibiotic tedizolid closely matched Zyvox (linezolid) in one of a series of pivotal studies, helping nail down support for
Rib-X touts positive PhIIb antibiotic data
Rib-X Pharmaceuticals , which is mounting an $80 million IPO effort, is touting positive midstage data from the Phase IIb study of its antibiotic delafloxacin. "Delafloxacin met or exceeded primary
Sanofi antibiotics partner Rib-X aims for $80M IPO
Antibiotics developer Rib-X Pharmaceuticals wants to go public after burning through more than $238 million since 2000. The New Haven, CT-based company hasn't said how many shares it plans to sell in
Sanofi teams with Rib-X on new crop of antibiotics
Sanofi is stepping out into the antibiotic field with an ambitious new development program it's formed with New Haven, CT-based Rib-X . In the deal Sanofi will hand over $10 million upfront and $9
Rib-X's antibiotic pipeline garners $20M in funding
With Warburg Pincus leading the way, Rib-X has landed $20 million in venture capital funding to support development of its antibiotic pipeline. Rib-X's main objective is to begin a Phase IIb study
Leuchtenberger takes reins at Rib-X
Mark Leuchtenberger, who tried, and failed, to develop an antibiotic at Targanta, is getting another crack at the same target. Leuchtenberger has been hired to take over as CEO of Rib-X in New Haven,
Rib-X antibiotic results prompt search for partner
New Haven, CT-based Rib-X is touting results from a Phase II clinical trial of radezolid, a treatment for mild to moderate community-acquired pneumonia. In a study of 160 patients at three different
